Results 41 to 50 of about 411,617 (199)

Insulin Degludec in the Management of Hyperglycemia in Pregnancy: Real-World Evidence on Glycemic Control and Outcomes

Journal of Diabetology
Introduction: Insulin degludec is an ultra-long-acting basal insulin characterized by low day-to-day variability compared to first-generation basal insulins.
Rutul Gokalani, Piyush Desai, Manoj Chawla, Dipak Chudasama, Subhajyoti Ghosh, Abhishek Srivastava, Vrunda Bhatt, Deepak Kumar Das, Aswin Mukundan, Munjal Pandya, Banshi Saboo   +10 more
doaj   +1 more source

Hypoglycemia in Type 2 Diabetes Patients Substituted with Insulin Degludec Aspart from Premixed Insulin Therapy: a Quasi Experimental Study

Pakistan Armed Forces Medical Journal
Objective: To determine whether Insulin Degludec Aspart is associated with a reduced risk of hypoglycemia as compared to premixed Insulin aspart therapy in type-2 diabetes mellitus patients. Study Design: Quasi-experimental study Place and Duration
Komal Mumtaz Malik, Sadia Zafar, Shabana Ali, Mudassir Noor, Noaman Ishaq   +4 more
doaj   +1 more source

Cost analysis of insulin degludec in comparison with insulin detemir in treatment of children and adolescents with type 1 diabetes in the UK

BMJ Open Diabetes Research & Care, 2019
Objective With healthcare systems under increasing financial pressure from costs associated with diabetes care, it is important to assess which treatments provide clinical benefits and represent best value.
Nandu Thalange, Jens Gundgaard, Witesh Parekh, Deniz Tutkunkardas   +3 more
doaj   +1 more source

Body Composition Remodelling During GLP‐1‐Based Therapy: A Systematic Review and Meta‐Analysis Using a Hierarchical Physiological Framework

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 9849-9860, November 2026.
ABSTRACT Background Body composition changes during glucagon‐like peptide‐1 (GLP‐1)‐based therapy remain incompletely characterized, particularly regarding their effects on adiposity, muscle quantity, and muscle quality. We conducted a systematic review and meta‐analysis using a predefined physiological framework to evaluate body composition ...
Maria Luizza Lopes Menezes, Maria Eduarda Güntzel Chiappa, Rodrigo Fuentes Kloss, Marcelo Tuesta, Paula Santos, Alberto Souza Sá Filho, Gaspar R. Chiappa   +6 more
wiley   +1 more source

Insulin Efsitora Demonstrates Similar Efficacy and Safety Profiles to Insulin Icodec in Insulin‐Experienced Individuals With Type 2 Diabetes Mellitus: Matching‐Adjusted Indirect Comparisons of QWINT‐3 Versus ONWARDS 2, and QWINT‐4 Versus ONWARDS 4

Diabetes, Obesity and Metabolism, Volume 28, Issue 11, Page 10725-10735, November 2026.
ABSTRACT Aims To conduct indirect treatment comparisons (ITCs) of insulin efsitora alfa (efsitora) versus insulin icodec (icodec) in insulin‐experienced individuals with Type 2 Diabetes Mellitus. Methods Efficacy, safety and patient reported outcomes were compared via matching‐adjusted ITCs using results from randomised controlled trials: QWINT‐3 ...
Harpreet S. Bajaj, Marvin Fischer, Michael B. Davidson, Abdul M. Tarafder, Christopher J. Michaels, Rachel H. Tao, Alex Pashley, Jess Amis, Josefine Redig   +8 more
wiley   +1 more source

Data on the first experience of insulin degludec (Tresiba®) treatment for type 2 diabetes in daily clinical practice

Сахарный диабет, 2015
Aim: The aim of this study was to evaluate the efficacy and safety of the new ultra-long-acting insulin degludec (Tresiba®) in the treatment of type 2 diabetes in routine clinical practice.Methods: This primary health care clinical observational study ...
Lyudmila Alexandrovna Suplotova, Nikolay Valer'evich Plotnikov, Natal'ya Valer'yanovna Romanova, Larisa Nikolaevna Bel’chikova, Ekaterina Viktorovna Khieva, Marina Vladimirovna Shestakova   +5 more
doaj   +1 more source

Low Weight Loss Response to Incretin Analogs: A Systematic Review

Obesity Reviews, Volume 27, Issue 11, November 2026.
ABSTRACT The development of GLP‐1 and GIP analogs has been a significant breakthrough in type 2 diabetes and obesity pharmacotherapy. However, individual responses to these medications can vary widely. This systematic review examines factors associated with low or no weight loss response to GLP‐1 and GIP analogs. Key predictors of poor response include
Pamela S. Gaskin, Peter S. Chami
wiley   +1 more source

En jämförande litteraturstudie över säkerheten av behandling av insulin degludec och insulin glargin hos diabetes typ-2 patienter med risk för hypoglykemi : En jämförande litteraturstudie över säkerheten av behandling av insulin degludec och insulin glargin hos diabetes typ-2 patienter med risk för hypoglykemi

, 2023
Sammanfattning Bakgrund: Typ 2-diabetes är en kronisk sjukdom som innebär att kroppen har svårt att reglera blodsockernivån. Det beror på att insulinresistens har utvecklats viket innebär att insulinet som produceras inte fungerar som det ska ...
Affan, Yara
core   +3 more sources

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9091-9100, October 2026.
ABSTRACT Aims To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by baseline age, Type 2 diabetes (T2D) duration and glycated haemoglobin (HbA1c) in the Soli‐D study.
Saichun Zhang, Yunjuan Gu, Yu Cheng, Ying Hu, Bing Li, Agustina Alvarez, Felipe Lauand, Lydie Melas‐Melt, Minlu Zhang, Yini Jiang, Qin Du, Lei Kang, Yiming Mu, Weijun Gu, Hongyu Kuang   +14 more
wiley   +1 more source

Insulin/carbohydrates ratio during the first 6‐month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study

Endocrinology, Diabetes & Metabolism, 2020
Background No data exist about the changes induced by the transition from first‐generation long‐acting insulins to second‐generation long‐acting analogues in the paediatric population.
Stefano Tumini, Olimpia Iacono, Laura Comegna, Elisabetta Fioretti, Paola Guidone, Gabriella Levantini, Daniele Panichi, Milena Catenaro, Ilaria Rossi, Flavia Amaro, Giusi Graziano, Maria Chiara Rossi, Paola Cipriano   +12 more
doaj   +1 more source